Adam Levy - Jul 11, 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
CFO and Secretary
Signature
/s/ Adam Levy
Stock symbol
MLYS
Transactions as of
Jul 11, 2025
Transactions value $
-$155,454
Form type
4
Date filed
7/15/2025, 05:01 PM
Previous filing
Apr 15, 2025
Next filing
Jul 30, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Levy Adam Scott CFO and Secretary 150 N. RADNOR CHESTER ROAD,, SUITE F200, RADNOR /s/ Adam Levy 2025-07-15 0001693134

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Sale -$155K -10.8K -4.95% $14.45 207K Jul 11, 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.3012 to $14.6546. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 This balance includes 2,030 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.